BACKGROUND: In retrospective studies, loss of p27(Kip1) (p27), a cyclin-dependent kinase inhibitor, has been associated with poor prognosis following colorectal cancer treatment. In a prospective study, we validated this relationship in patients enrolled on a trial of adjuvant chemotherapy for stage III colon cancer. METHODS:Cancer and Leukemia Group B protocol 89803 randomized 1,264 stage III colon cancer patients to receive weekly bolus 5-fluorouracil/leucovorin or weekly bolus irinotecan, 5-fluorouracil, and leucovorin (IFL). The primary endpoint was overall survival (OS); disease-free survival was a secondary endpoint. Expression of p27 and DNA mismatch repair proteins were determined by immunohistochemistry in primary tumor and normal tissue from paraffin blocks. Data were analyzed using log-rank test. RESULTS: Of 601 tumors analyzed, 207 (34.4%) showed p27 loss, 377 (62.8%) retained p27, and 17 (2.8%) were indeterminate. Patients with p27-negative tumors showed reduced OS [5-year OS 66%: 95% confidence interval (95% CI), 0.59-0.72 versus 75%: 95% CI, 0.70-0.79; log-rank P = 0.021]. This relationship was not influenced by treatment arm. Combination of p27 status with mismatch repair status, however, identified a small subset of patients that may benefit from IFL (n = 36; 5-year disease-free survival 81%: 95% CI, 0.64-0.98 versus 47%: 95% CI, 0.21-0.72; log-rank P = 0.042; 5-year OS 81%: 95% CI, 0.64-0.98 versus 60%: 95% CI, 0.35-0.85; log-rank P = 0.128). CONCLUSIONS: Loss of p27 is associated with reduced survival in stage III colon cancer but by itself does not indicate a significant difference in outcome between patients treated IFL or 5-fluorouracil/leucovorin.
RCT Entities:
BACKGROUND: In retrospective studies, loss of p27(Kip1) (p27), a cyclin-dependent kinase inhibitor, has been associated with poor prognosis following colorectal cancer treatment. In a prospective study, we validated this relationship in patients enrolled on a trial of adjuvant chemotherapy for stage III colon cancer. METHODS:Cancer and Leukemia Group B protocol 89803 randomized 1,264 stage III colon cancerpatients to receive weekly bolus 5-fluorouracil/leucovorin or weekly bolus irinotecan, 5-fluorouracil, and leucovorin (IFL). The primary endpoint was overall survival (OS); disease-free survival was a secondary endpoint. Expression of p27 and DNA mismatch repair proteins were determined by immunohistochemistry in primary tumor and normal tissue from paraffin blocks. Data were analyzed using log-rank test. RESULTS: Of 601 tumors analyzed, 207 (34.4%) showed p27 loss, 377 (62.8%) retained p27, and 17 (2.8%) were indeterminate. Patients with p27-negative tumors showed reduced OS [5-year OS 66%: 95% confidence interval (95% CI), 0.59-0.72 versus 75%: 95% CI, 0.70-0.79; log-rank P = 0.021]. This relationship was not influenced by treatment arm. Combination of p27 status with mismatch repair status, however, identified a small subset of patients that may benefit from IFL (n = 36; 5-year disease-free survival 81%: 95% CI, 0.64-0.98 versus 47%: 95% CI, 0.21-0.72; log-rank P = 0.042; 5-year OS 81%: 95% CI, 0.64-0.98 versus 60%: 95% CI, 0.35-0.85; log-rank P = 0.128). CONCLUSIONS: Loss of p27 is associated with reduced survival in stage III colon cancer but by itself does not indicate a significant difference in outcome between patients treated IFL or 5-fluorouracil/leucovorin.
Authors: P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts Journal: Nat Med Date: 1997-02 Impact factor: 53.440
Authors: S N Thibodeau; A J French; P C Roche; J M Cunningham; D J Tester; N M Lindor; G Moslein; S M Baker; R M Liskay; L J Burgart; R Honchel; K C Halling Journal: Cancer Res Date: 1996-11-01 Impact factor: 12.701
Authors: J Tsihlias; L R Kapusta; G DeBoer; I Morava-Protzner; I Zbieranowski; N Bhattacharya; G C Catzavelos; L H Klotz; J M Slingerland Journal: Cancer Res Date: 1998-02-01 Impact factor: 12.701
Authors: V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano Journal: Cancer Res Date: 1997-08-15 Impact factor: 12.701
Authors: N Kawamata; R Morosetti; C W Miller; D Park; K S Spirin; T Nakamaki; S Takeuchi; Y Hatta; J Simpson; S Wilcyznski Journal: Cancer Res Date: 1995-06-01 Impact factor: 12.701
Authors: Brandon J Walters; Wenwei Lin; Shiyong Diao; Mark Brimble; Luigi I Iconaru; Jennifer Dearman; Asli Goktug; Taosheng Chen; Jian Zuo Journal: PLoS One Date: 2014-03-19 Impact factor: 3.240